For example, the determination of antigen levels of uPA and PAI-1 in tissue extracts of primary breast cancer has entered clinical practice for risk-adapted, individual therapy decisions in patients with lymph node-negative disease [11,26]. Here, PLAU is linked to breast carcinoma.